Cargando…
Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter
Background and Aims: Inflammatory bowel diseases (IBD) are frequently associated with extraintestinal manifestations, hepatic injury being of concern in these patients. Current literature reports an increased prevalence of liver steatosis and fibrosis in subjects with IBD and the pathophysiology is...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573563/ https://www.ncbi.nlm.nih.gov/pubmed/36233826 http://dx.doi.org/10.3390/jcm11195959 |
_version_ | 1784810903735107584 |
---|---|
author | Trifan, Anca Stafie, Remus Rotaru, Adrian Stratina, Ermina Zenovia, Sebastian Nastasa, Robert Huiban, Laura Cuciureanu, Tudor Muzica, Cristina Chiriac, Stefan Girleanu, Irina Singeap, Ana-Maria Sfarti, Catalin Cojocariu, Camelia Petrea, Oana Stanciu, Carol |
author_facet | Trifan, Anca Stafie, Remus Rotaru, Adrian Stratina, Ermina Zenovia, Sebastian Nastasa, Robert Huiban, Laura Cuciureanu, Tudor Muzica, Cristina Chiriac, Stefan Girleanu, Irina Singeap, Ana-Maria Sfarti, Catalin Cojocariu, Camelia Petrea, Oana Stanciu, Carol |
author_sort | Trifan, Anca |
collection | PubMed |
description | Background and Aims: Inflammatory bowel diseases (IBD) are frequently associated with extraintestinal manifestations, hepatic injury being of concern in these patients. Current literature reports an increased prevalence of liver steatosis and fibrosis in subjects with IBD and the pathophysiology is yet to be completely understood. The aim of this study was to assess the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with IBD, as well as to determine the factors that connect these two disorders. Methods: From September 2021 to June 2022, 82 consecutive IBD patients were enrolled from a tertiary care center hospital in Iasi. Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter (CAP) was used to assess the presence of NAFLD, with a cut-off score for CAP of 248 dB/m. Significant liver fibrosis was considered at a cut-off for liver stiffness measurements (LSM) of 7.2 kPa. Results: In total, 82 IBD patients (54.8% men, mean age of 49 ± 13 years) were included, 38 (46.3%) of them being diagnosed with NAFLD, with a mean CAP score of 286 ± 35.4 vs. 203 ± 29.7 in patients with IBD only. Age (β = 0.357, p = 0.021), body mass index (BMI) (β = 0.185, p = 0.048), disease duration (β = 0.297, p = 0.041), C—reactive protein (β = 0.321, p = 0.013), fasting plasma glucose (β = 0.269, p = 0.038), and triglycerides (β = 0.273, p = 0.023) were strongly associated with the presence of liver steatosis. The multivariate analysis showed that older age, BMI, and disease duration were strongly associated with significant liver fibrosis in our group. Conclusions: NAFLD is a multifaced pathology with growing prevalence among IBD patients. Additional studies are needed to completely understand this problem and to create a solid evidence-based framework for more effective preventative and intervention strategies. |
format | Online Article Text |
id | pubmed-9573563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95735632022-10-17 Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter Trifan, Anca Stafie, Remus Rotaru, Adrian Stratina, Ermina Zenovia, Sebastian Nastasa, Robert Huiban, Laura Cuciureanu, Tudor Muzica, Cristina Chiriac, Stefan Girleanu, Irina Singeap, Ana-Maria Sfarti, Catalin Cojocariu, Camelia Petrea, Oana Stanciu, Carol J Clin Med Article Background and Aims: Inflammatory bowel diseases (IBD) are frequently associated with extraintestinal manifestations, hepatic injury being of concern in these patients. Current literature reports an increased prevalence of liver steatosis and fibrosis in subjects with IBD and the pathophysiology is yet to be completely understood. The aim of this study was to assess the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with IBD, as well as to determine the factors that connect these two disorders. Methods: From September 2021 to June 2022, 82 consecutive IBD patients were enrolled from a tertiary care center hospital in Iasi. Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter (CAP) was used to assess the presence of NAFLD, with a cut-off score for CAP of 248 dB/m. Significant liver fibrosis was considered at a cut-off for liver stiffness measurements (LSM) of 7.2 kPa. Results: In total, 82 IBD patients (54.8% men, mean age of 49 ± 13 years) were included, 38 (46.3%) of them being diagnosed with NAFLD, with a mean CAP score of 286 ± 35.4 vs. 203 ± 29.7 in patients with IBD only. Age (β = 0.357, p = 0.021), body mass index (BMI) (β = 0.185, p = 0.048), disease duration (β = 0.297, p = 0.041), C—reactive protein (β = 0.321, p = 0.013), fasting plasma glucose (β = 0.269, p = 0.038), and triglycerides (β = 0.273, p = 0.023) were strongly associated with the presence of liver steatosis. The multivariate analysis showed that older age, BMI, and disease duration were strongly associated with significant liver fibrosis in our group. Conclusions: NAFLD is a multifaced pathology with growing prevalence among IBD patients. Additional studies are needed to completely understand this problem and to create a solid evidence-based framework for more effective preventative and intervention strategies. MDPI 2022-10-09 /pmc/articles/PMC9573563/ /pubmed/36233826 http://dx.doi.org/10.3390/jcm11195959 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Trifan, Anca Stafie, Remus Rotaru, Adrian Stratina, Ermina Zenovia, Sebastian Nastasa, Robert Huiban, Laura Cuciureanu, Tudor Muzica, Cristina Chiriac, Stefan Girleanu, Irina Singeap, Ana-Maria Sfarti, Catalin Cojocariu, Camelia Petrea, Oana Stanciu, Carol Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter |
title | Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter |
title_full | Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter |
title_fullStr | Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter |
title_full_unstemmed | Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter |
title_short | Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter |
title_sort | screening for liver steatosis and fibrosis in patients with inflammatory bowel disease using vibration controlled transient elastography with controlled attenuation parameter |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573563/ https://www.ncbi.nlm.nih.gov/pubmed/36233826 http://dx.doi.org/10.3390/jcm11195959 |
work_keys_str_mv | AT trifananca screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT stafieremus screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT rotaruadrian screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT stratinaermina screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT zenoviasebastian screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT nastasarobert screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT huibanlaura screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT cuciureanutudor screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT muzicacristina screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT chiriacstefan screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT girleanuirina screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT singeapanamaria screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT sfarticatalin screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT cojocariucamelia screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT petreaoana screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT stanciucarol screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter |